Angiotensin-converting enzyme (ACE) inhibitor therapy after myocardial infarction in relation to left ventricular function

被引:3
作者
Reikvam, A [1 ]
Kvan, E [1 ]
Landmark, K [1 ]
Aursnes, I [1 ]
机构
[1] Univ Oslo, Fac Med, Dept Pharmacotherapeut, NO-0316 Oslo, Norway
关键词
cardiovascular drugs; heart failure; myocardial infarction; therapy;
D O I
10.1080/14017430310005821
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To investigate to what extent and by what methods clinicians assess left ventricular (LV) function after an acute myocardial infarction (AMI) and how the results of the assessments relate to the use of angiotensin-converting enzyme (ACE) inhibitors; furthermore, to explore which main indications caused the clinicians to initiate ACE inhibitor therapy. Design-From 16 hospitals we drew a sample of patients who were discharged with the diagnosis of AMI during a 3-month period in 1999/2000. Physicians in each hospital obtained the observed rate of use of cardiovascular drugs at discharge and also information on ejection fraction (EF) measurements. The results of the EF recordings were classified into three categories: >0.50, 0.40-0.50 and <0.40. The clinicians' main indications for drug use were reported. Results-Among 767 patients discharged alive, EF was measured in 409 (53%), by echocardiography in 53% and by radionuclide ventriculography in 47%. Of the 409 patients 227 (55%) had EF >0.50,95 (24%) EF 0.40-0.50 and 87 (21%) EF <0.40. Adjusted odds ratio for ACE inhibitor therapy being initiated during the AMI was 13.5 for those with EF <0.40 compared with those with EF >0.50. The main indication for starting ACE inhibitor therapy was heart failure (50%) followed by secondary prevention (42%). Conclusion-Measuring EF appears to be an important tool in the evaluation of AMI patients prior to discharge from hospital. Initiation of ACE inhibitor therapy related strongly to the results of the assessments.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 18 条
  • [1] BALL SG, 1993, LANCET, V342, P821
  • [2] COLLINS R, 1995, LANCET, V345, P669
  • [3] DEVITA C, 1994, LANCET, V343, P1115
  • [4] Fox KM, 1998, EUR HEART J, V19, pJ52
  • [5] GARDNER MJ, 1989, STAT CONFIDENCE
  • [6] Hole T, 2002, Eur J Echocardiogr, V3, P263, DOI 10.1016/S1525-2167(02)90167-8
  • [7] Comparison of different echocardiographic methods with radionuclide imaging for measuring left ventricular ejection fraction during acute myocardial infarction treated by thrombolytic therapy
    Jensen-Urstad, K
    Bouvier, F
    Hojer, J
    Ruiz, H
    Hulting, J
    Samad, B
    Thorstrand, C
    Jensen-Urstad, M
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (05) : 538 - 544
  • [8] A CLINICAL-TRIAL OF THE ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR TRANDOLAPRIL IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION
    KOBER, L
    TORPPEDERSEN, C
    CARLSEN, JE
    BAGGER, H
    ELIASEN, P
    LYNGBORG, K
    VIDEBEK, J
    COLE, DS
    AUCLERT, L
    PAULY, NC
    ALIOT, E
    PERSSON, S
    CAMM, AJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) : 1670 - 1676
  • [9] NICKLAS JM, 1992, NEW ENGL J MED, V327, P685
  • [10] EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION - RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL
    PFEFFER, MA
    BRAUNWALD, E
    MOYE, LA
    BASTA, L
    BROWN, EJ
    CUDDY, TE
    DAVIS, BR
    GELTMAN, EM
    GOLDMAN, S
    FLAKER, GC
    KLEIN, M
    LAMAS, GA
    PACKER, M
    ROULEAU, J
    ROULEAU, JL
    RUTHERFORD, J
    WERTHEIMER, JH
    HAWKINS, CM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (10) : 669 - 677